Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion
Condition(s) studied
Investigational drug(s) / intervention(s)
Investigational PFO Closure Device: Occlutech Flex II PFO Closure Device
Standard of Care PFO Closure Device: Amplatzer PFO Occluder and Gore Cardioform PFO Occluder
Study summary
The objective of this study is to investigate whether percutaneous PFO closure with the Occlutech Flex II PFO Occluder is non-inferior to the AMPLATZER™ PFO Occluder and Gore® Cardioform Septal Occluder in closure of the PFO, prevention of recurrent embolic stroke, and device/procedure related Serious Adverse Events (SAE).
Eligibility
Primary outcome measure(s)
- Effective Closure Rate of PFO — Twelve Months
Trial sites (48)
| Facility | City | Region | Status |
|---|---|---|---|
| Arizona Cardiovascular Research Center | Phoenix | Arizona | |
| Stanford University Medical Center | Stanford | California | |
| Los Robles Medical Center | Thousand Oaks | California | |
| Colorado Heart and Vascular PC / St. Anthony Hospital | Lakewood | Colorado | |
| South Denver Cardiology Associates | Littleton | Colorado | |
| Medstar Washington Hospital Center | Washington D.C. | District of Columbia | |
| Rush University Medical Center | Chicago | Illinois | |
| OSF Saint Francis Medical Center | Peoria | Illinois | |
| University of Louisville | Louisville | Kentucky | |
| MaineHealth | Portland | Maine | |
| Tufts New England Medical Center | Boston | Massachusetts | |
| Massachusetts General Hospital | Boston | Massachusetts | |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | |
| Baystate Medical Center | Springfield | Massachusetts | |
| University of Michigan | Ann Arbor | Michigan | |
| Essentia Health | Duluth | Minnesota | |
| University of Nebraska Medical Center | Omaha | Nebraska | |
| The Valley Hospital | Paramus | New Jersey | |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | |
| The Ohio State University | Columbus | Ohio | |
| Ohio Health Research Institute | Columbus | Ohio | |
| Oklahoma Heart Hospital | Oklahoma City | Oklahoma | |
| Oregon Health & Science University | Portland | Oregon | |
| UPMC Presbyterian | Pittsburgh | Pennsylvania | |
| Vanderbilt Medical Center | Nashville | Tennessee | |
| HCA Houston Healthcare Medical Center | Houston | Texas | |
| University of Texas Health Science Center at Houston | Houston | Texas | |
| University of Alberta Mazankowski Heart Institute | Edmonton | Alberta | |
| Vancouver General Hospital | Vancouver | British Columbia | |
| Ottawa Heart Institute | Ottawa | Ontario | |
| Toronto General Hospital | Toronto | Ontario | |
| Centre Hospitalier de l'Université de Montreal (CHUM) | Montreal | Quebec | |
| Institut de Cardiologie de Montréal | Montreal | Quebec | |
| Aarhus University Hospital | Aarhus | Denmark | |
| Rigshospitalet Copenhagen | Copenhagen | Denmark | |
| Heart and Lung Center, Helsinki University Hospital | Helsinki | Finland | |
| CHU Grenoble Alpes | La Tronche | France | |
| Hôpital Privé Jacques Cartier | Massy | France | |
| CHU Toulouse Rangueil | Toulouse | France | |
| CardioVasculäre Centrum Frankfurt | Frankfurt | Germany |
+ 8 more sites — see the full list on the official registry below.
More Occlutech International AB trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05069558 on ClinicalTrials.gov ↗ ← All trials in France